Allosteric modulators of G-protein-coupled receptors can regulate conformational states involved in receptor activation (Hall DA (2000) Modeling the functional effects of allosteric modulators at pharmacological receptors: an extension of the two-state model of receptor activation. Mol Pharmacol 58:1412-1423). This hypothesis was investigated for the corticotropin-releasing factor type 1 (CRF 1 ) receptor, using a novel series of ligands with varying allosteric effect on CRF binding (inhibition to enhancement). For the G-protein-uncoupled receptor, allosteric modulation of CRF binding was correlated with nonpeptide ligand signaling activity; inverse agonists inhibited and agonists enhanced CRF binding. These data were quantitatively consistent with a two-state equilibrium underlying the modulation of CRF binding to the G-protein-uncoupled receptor. We next investigated the allosteric effect on CRF-stimulated G-protein Nonpeptide antagonists targeting the corticotropin-releasing factor (CRF) type 1 receptor have been developed as potential treatments for anxiety and depression (Kehne and De Lombaert, 2002) . The development of these ligands has been stimulated by the hypothesis that anxiety and depression are stress-related disorders (Holsboer, 2001) and by the established role of CRF as a principal regulator of the stress axis (Bale and Vale, 2004) . CRF is a 41 amino-acid peptide that regulates the hypothalamic-pituitary axis (Bale and Vale, 2004) . CRF is secreted from the hypothalamus and stimulates the release of ACTH from pituitary corticotropes, which in turn stimulates corticosteroid release from the adrenal medulla. CRF also acts on CRF 1 receptors in cerebral cortical and limbic nuclei regulating behavior (Smagin et al., 2001) . Studies of the physiology and pathophysiology of the CRF system in animal models and humans implicate antagonism of central CRF 1 receptors as a potential, novel mechanism for treating anxiety, depression and other stress-related disorders (Holsboer, 2001; Smagin et al., 2001 ).
acenaphthylene; NBI 77172, (S)-6-phenyl-2-(2,4-dichlorophenyl)-4-methyl-7-benzyl-7,8-dihydro-6H-1,3,6,8a-tetraaza-acenaphthylene; NBI 77173, (R)-6-cyclopropylmethyl-2-(2,4-dichlorophenyl)-4-methyl-7-benzyl-7,8-dihydro-6H-1,3,6,8a-tetraazaacenaphthylene; NBI 77178, (R)-6-phenyl-2-(2,4-dichlorophenyl)-4-methyl-7-benzyl-7,8-dihydro-6H-1,3,6,8a-tetraaza-acenaphthylene; R, inactive receptor state; R*, weakly active receptor state; R**, fully active receptor state; SAR, structure-activity relationship.
MOL #42978 5 affinity (Hoare et al., 2004) . CRF can then interact readily with the transmembrane domain, thereby activating the receptor and intracellular signaling (stimulation of adenylyl cyclase activity) (Hoare et al., 2004; Nielsen et al., 2000) . CRF binds to determinants in the extracellular loops and extracellular-proximal regions of the predicted membrane-spanning α-helices (Assil-Kishawi and Abou-Samra, 2002; Dautzenberg et al., 2002; Kraetke et al., 2005; Liaw et al., 1997) . Nonpeptide antagonists bind more centrally within the transmembrane domain (Hoare et al., 2006; Liaw et al., 1997) , and allosterically inhibit CRF interaction with its spatially-distinct binding determinants on the transmembrane domain (Hoare et al., 2004) . This allosteric inhibition blocks the CRF interaction required to activate the receptor, resulting in antagonism.
The conformational basis of this allosteric modulation of the CRF 1 receptor remains largely unknown. Multiple conformational states of the CRF 1 receptor have been inferred, differing in the mechanism of their desensitization (Perry et al., 2005) or in their ligand affinity (e.g. G-protein coupled and uncoupled states, with high and low affinity for agonists, respectively (Hoare et al., 2003) ). Nonpeptide ligands strongly inhibit CRF binding to the G-protein-coupled state but weakly inhibit binding to the uncoupled receptor (Hoare et al., 2003) . GPCR's in general are conformationally heterogeneous, and exploiting this dynamic nature in drug discovery has received considerable recent attention (Kenakin, 2007; Kobilka and Deupi, 2007) . Biophysical studies of rhodopsin, a Class A GPCR, have identified multiple conformational states associated with receptor activation (Hubbell et al., 2003) . Fluorescence spectroscopy applied to Class A GPCR's activated by diffusible ligands has also directly demonstrated discrete conformational states that vary with respect to their capacity to activate G-protein or undergo MOL #42978 6 desentitization (Ghanouni et al., 2001; Kobilka and Deupi, 2007; Nikolaev et al., 2006; Swaminath et al., 2004) . Pharmacological data and modeling are consistent with multiple conformations of GPCR's with differential ability to selectively target specific downstream receptor signaling and / or desensitization pathways (Kenakin, 2007) .
Conformational states involved in GPCR activation are involved in the mechanism of action of some allosteric modulators. A general model combining the allosteric ternary model of modulator action with the two-state model of receptor activation explains the mechanism of action of several allosteric ligands (Bruns and Fergus, 1990; Hall, 2000) . Allosteric modulators of Class C GPCR's modulate multiple conformational states involved in receptor activation (Parmentier et al., 2002) . These findings prompted us to explore the hypothesis that allosteric modulation of the CRF 1 receptor by nonpeptide ligands involves regulation of conformational states involved in receptor activation, and to investigate the extent to which different ligands vary in their capacity to modulate these states.
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Materials and Methods
Materials -Rat/human CRF, [Tyr 0 ]astressin (Miranda et al., 1994) and Peptide 19
(peptide number 19 of (Yamada et al., 2004) ) were synthesized by solid phase methodology on a Beckman Coulter 990 peptide synthesizer (Fullerton, CA) using t-Bocprotected amino acids. The assembled peptide was de-protected with hydrogen fluoride and purified by preparative HPLC. The purity of the final product, assessed by analytical HPLC and mass spectrometric analysis using an ion-spray source, was > 95%. The peptides were dissolved in 10mM acetic acid / 0.1% bovine serum albumin at a Nonpeptide ligands were synthesized as described in (Gross et al., 2005) for NBI 35965
(compound 12a of this reference, (S)-6-cyclopropylmethyl-2-(2,4-dichlorophenyl)-7-ethyl-4-methyl-7,8-dihydro-6H-1,3,6,8a-tetraaza-acenaphthylene), NBI 38242 -ethyl-4-methyl-7,8-dihydro-6H-1,3,6,8a-tetraaza-acenaphthylene) , and NBI 34041 (compound 12t, 2-(2,4-
,8a-tetraaza-acenaphthylene) was synthesized as described in (Gross et al., 2005) using the appropriate intermediate used to prepare compound 12g of this reference and alkylating using benzyl bromide. NBI 77173 ((R)-6-cyclopropylmethyl-2-(2,4-dichlorophenyl)-4-methyl-7-benzyl-7,8-dihydro-6H-1,3,6,8a-tetraazaacenaphthylene) and NBI 77178 ((R)-6-phenyl-2-(2,4-dichlorophenyl)-4-methyl-7-MOL #42978 8 benzyl-7,8-dihydro-6H-1,3,6,8a-tetraaza-acenaphthylene) were synthesized using the (R) enantiomer of the appropriate intermediate, as described in (Gross et al., 2005) and alkylating with bromomethylcyclopropane and benzyl bromide, respectively. NBI 30775 was synthesized as described (Chen et al., 2004 ) (compound 26h, 2,5-dimethyl-3-(6-dimethyl-4-methylpyridin-3-yl)-7-dipropylaminopyrazolo[1,5-a]pyrimidine). Nonpeptide ligands were dissolved in 100% dimethylsulfoxide at a concentration of 10 mM and stored at -20 °C.
3 H-NBI 35965 was prepared as described previously (Hoare et al., 2006) . G418 (geneticin), Dulbecco's phosphate-buffered saline (DPBS) and cell culture supplies were from Invitrogen (Carlsbad, CA). Fetal bovine serum was from HyClone (Logan, UT). Pertussis toxin was from EMD Biosciences (San Diego, CA). AtT-20/D16v-F2 cells were obtained from American Type Culture Collection (Manassas, VA).
Cell culture and preparation of cell membranes -A CHO cell line was used for detection of constitutive receptor activity in whole cell cAMP assays (St-Denis et al., 2005 ) that highly over-expresses the human CRF 1 receptor ( 125 I-astressin B max 100 ± 20 pmol/mg).
MOL #42978
was used that has been extensively characterized in radioligand binding experiments, with a B max of 28 ± 6 pmol/mg membrane protein (Hoare et al., 2006) . Cell membranes were prepared from these cells using nitrogen cavitation and differential centrifugation as described previously (Hoare et al., 2003) .
cAMP accumulation assays -Accumulation of cAMP was measured in CHO-CRF 1 and AtT20 cells plated 18 hours prior to the assay into 96-well plates (poly-lysine coated for AtT20 cells). In initial experiments on CHO-CRF 1 cells, a bell-shaped CRF concentration-dependence curve was observed. The descending, inhibitory component of this curve was blocked by including pertussis toxin when plating the cells, consistent with coupling to inhibitory G-proteins. Consequently, CHO-CRF 1 cells were plated with 100 ng/ml pertussis toxin, 18 hours prior to the assay. CHO-CRF 1 cells were plated at a density of 5,000 cells/well and AtT20 cells were plated in the absence of pertussis toxin at a cell density of 27,000-40,000 cells/well. For the assay, medium was removed, and the cells were washed with 150 µl DPBS. Following aspiration of DPBS, 75 µl cAMP assay buffer was added to each well (DMEM without phenol red, supplemented with 2 mM glutamine, 1 mM sodium pyruvate, 10 mM HEPES, 50 IU/ml penicillin, 50 µg/ml streptomycin and 1 mM 3-isobutyl-1-methylxanthine). Ligands were then added in a volume of 25 µl. In experiments in which more than one compound was included in the assay (receptor ligand with forskolin or peptide with nonpeptide ligand), compounds were diluted together prior to addition to the assay so that cells were exposed simultaneously to the two ligands. Cells were incubated for 30 min at 37 °C in 5 % CO 2 .
cAMP was measured by chemiluminescent immunoassay (Tropix, Bedford, MA). Alto, CA). All assays were incubated for 2 hours at 22°C , followed by separation of bound and free radioligand by rapid filtration and radioactivity counting as described previously (Hoare et al., 2003) . The wash buffer employed in the filtration step was In the first series of binding experiments, the effect of nonpeptide ligand on CRF binding to the G-protein-uncoupled state of the receptor was measured, using a method described previously (Hoare et al., 2003 
where R is receptor, L* is peptide radioligand ( 125 I-astressin), L is unlabeled peptide ligand (CRF), N is nonpeptide allosteric modulator, K L* , K L and K N are the corresponding equilibrium dissociation constants, C L* is the observed cooperativity between nonpeptide and radioligand (denoted C astressin in Table 1 ), C L is the observed cooperativity between nonpeptide and unlabeled peptide ligand (denoted C CRF in Table 1 ), [R TOT ] is the total receptor concentration and NSB is nonspecific binding. This equation was derived as previously described (Hoare et al., 2003) . Total binding data (cpm) were fit to this equation using SigmaPlot 8.0 (SPSS Science, Chicago, IL) with the concentration of CRF and nonpeptide ligand as independent variables. NSB was assumed to be equal for all concentrations of nonpeptide ligand and was fitted as a common lower asymptote of the displacement curves.
Inhibition of 3 H-NBI 35965 and inhibition of GTPγS-sensitive 125 I-sauvagine binding by nonpeptide ligand was fit by a single-state inhibition equation using Prism 4.01 (GraphPad Software Inc., San Diego, CA), and the IC 50 was converted to K i using the method of Cheng and Prusoff (Cheng and Prusoff, 1973) . A sigmoid concentrationresponse equation (slope factor fixed at unity) was fit to cAMP accumulation data, using Prism 4.01. Initial analyses using a four parameter-logistic equation indicated the slope factor was close to unity in all assays (between 0.8 and 1.2).
Results
The aim of this study was to test the hypothesis that allosteric modulation by nonpeptide ligands involves modulation of conformational states associated with CRF 1 receptor activation. Previous studies indicate differences of allosteric effect by nonpeptide ligand depending on the conformational state of the CRF 1 receptor, with modest allosteric inhibition at the receptor uncoupled from G-protein, and strong inhibition at the G-protein-coupled receptor (Hoare et al., 2003) . We first investigated the allosteric mechanism at the uncoupled receptor.
Discovery of a series of nonpeptide ligands with a range of allosteric activity -To
facilitate this investigation we utilized a series of nonpeptide ligands displaying a range of allosteric activity on CRF binding. Allosteric modulation of CRF binding was measured using a 'triple-ligand' assay (Hoare et al., 2003) . 125 I-astressin was employed as the radioligand. Binding of this radioligand, predominantly to the ECD of the CRF 1 receptor (Perrin et al., 1998) , is not appreciably inhibited by nonpeptide ligands. 125 Iastressin binding is fully inhibited by CRF ( Fig. 2) , which binds the ECD and transmembrane domain of the receptor (Hoare et al., 2004) . The allosteric effect of nonpeptide ligand can then be evaluated by measuring its effect on the CRF inhibition curve for displacing 125 I-astressin binding. Finally, a high concentration of GTPγS was included in the assay, to uncouple receptor from G-protein, providing a read-out of the allosteric effect on receptor uncoupled from G-protein.
A prototypical antagonist NBI 35965 ( Table 1 ). We further explored the SAR of the R-configuration (Fig. 1C) . Strikingly, replacing the 7-ethyl group with phenyl (NBI 77173) changed the allosteric effect from inhibition to enhancement of CRF binding (C CRF of 9.0, indicating a 9-fold increase of CRF affinity, Table 1 ). This effect was evident as a leftward shift of the CRF inhibition curve (Fig. 2C) . Furthermore, additional replacement of the 6-cyclopropyl group with benzyl (NBI 77178) increased the allosteric enhancement (C CRF of 31, indicating a 31-fold increase of CRF affinity, Fig. 2D , Table 1 ). The SAR of this series was explored with two additional compounds (NBI 77165 and NBI 77172, Fig. 1C ) as summarized in Table 1 . In addition two compounds tested clinically acted as allosteric inhibitors (NBI 30775 and NBI 34041, Fig. 1A and B, Table 1 ). In summary, a series of nonpeptide ligands was identified which displayed a considerable range of allosteric effect on the Gprotein-uncoupled CRF 1 receptor, ranging from inhibition to enhancement of CRF binding. GPCR's (Hall, 2000) . In this model, receptor is in equilibrium between inactive and active states (R and R* respectively). A full agonist (e.g. CRF) binds preferentially to R* over R. Allosteric inhibition of agonist binding results from modulator stabilizing R, which binds agonist with lower affinity, whereas allosteric enhancement results from modulator stabilizing R*, which binds agonist with higher affinity. Within the two-state model, stabilization of R* vs R can be evaluated using the intrinsic activity (E max ) of the ligand; redistribution towards R* results in agonism, and reciprocally shifting the distribution towards R results in inverse agonism. We therefore tested the hypothesis that allosteric modulation of CRF binding results from changes of an R/R* equilibrium by measuring the intrinsic signaling activity of nonpeptide modulators (in the absence of CRF), and comparing the intrinsic activity values with those for allosteric modulation.
A highly sensitive signaling system was developed to detect efficacy of nonpeptide ligands (see Supplemental Information). The signaling response (stimulation of cAMP accumulation) was highly amplified by receptor over-expression (100 pmol / mg). Despite the very high level of receptor expression, constitutive activity could not be reliably detected, indicating very low constitutive activity of the CRF 1 receptor.
Constitutive activity could be detected using forskolin to amplify the response (see Supplemental Information). The conditions employed allowed detection of constitutive receptor activity, small partial agonist responses, and inverse agonism ( Table 2 ). The allosteric inhibitors NBI 30775 and NBI 34041 ( Table 2 ).
This finding suggests a correlation between allosteric modulation and signaling efficacy.
In Fig. 4 this correlation was quantified using additional ligands within the same series (NBI 38242, NBI 77165 and NBI 77172, Table 2 ). Linear regression indicated a significant correlation between allosteric modulation of CRF binding (C CRF ) and intrinsic activity of nonpeptide ligands (r 2 = 0.96, p < 0.0001, dashed line on Fig. 4) . The data were also well-fit by a sigmoid curve (r 2 = 0.98) with a slope-factor close to unity (1.2) and a y-intercept close to 100% (140%, solid line in Fig. 4 ). This correlation suggests allosteric modulation of CRF binding to the uncoupled receptor involves changes of receptor states involved in receptor activation, consistent with an inactive / active state equilibrium of the uncoupled receptor (Hall, 2000) . In Supplemental Information simulated data are used to demonstrate that such a model is quantitatively consistent with the correlation in Fig. 4 . The simulation predicts a sigmoidal relationship between C CRF and E max , with a slope factor of unity and a y-inercept of 100% (Fig. S2 ), in agreement with the experimental data (Fig. 4) . readily detected as a change of E max , whereas at high levels of expression changes of efficacy are manifest as changes of EC 50 , from which it is more complicated to ascertain the effect on agonist efficacy. AtT20 cells were used (Litvin et al., 1984) , which are mouse corticotrope cells that endogenously-express the CRF 1 receptor (100 fmol/mg). In AtT20 cells, CRF stimulated cAMP accumulation with an EC 50 of 2.2 nM (Fig. 5 ). In the absence of CRF, none of the nonpeptide modulators tested in this study affected cAMP accumulation in AtT20 cells (data not shown), in contrast to CHO-CRF 1 cells (Fig. 3) .
Allosteric modulation of CRF-stimulated G-protein-coupling by nonpeptide ligands
This difference is likely due to the high level of signal amplification via the overexpressed receptor in CHO-CRF 1 cells, amplifying responses that are not detectable via the endogenously-expressed receptor in AtT20 cells.
A ligand that allosterically inhibited CRF binding to the G-protein-uncoupled receptor (NBI 35965) antagonized the CRF response in AtT20 cells (Fig. 5A) .
Surprisingly, a ligand that allosterically enhanced CRF binding to the uncoupled receptor (NBI 77173) also inhibited the CRF response (Fig. 5B) (Montecucchi and Henschen, 1981) . This peptide shares critical amino acid sequence determinants with CRF that are responsible for CRF 1 receptor binding and activation (Montecucchi and Henschen, 1981) . Table 3 ). This effect was particularly pronounced for NBI 77178 (Fig. 6D , (Fig. S2) ; and the sigmoidal relationship between nonpeptide ligand E max and cooperativity with CRF (Fig. S3 ).
This article has not been copyedited and formatted. The final version may differ from this version. (Ghanouni et al., 2001; Nikolaev et al., 2006) . These different conformations have been proposed to represent conformational steps along a sequential receptor activation pathway (Swaminath et al., 2004) . (Fig. 5) , the different intrinsic activities of these two ligands could be significant in CRF 1 receptor regulation in the long-term exposure typical in antidepressant therapy. Different mechanisms of GPCR regulation result from treatment with ligands that stabilize different conformational states (Kenakin, 2007) , and for the CRF 1 receptor, different mechanisms of receptor internalization have been suggested to result from distinct conformational states (Perry et al., 2005) .
In Fig. 7 , the conformational model of Scheme 1 is combined with the current low-resolution two-domain molecular model of CRF and nonpeptide ligand binding (Grace et al., 2007; Hoare et al., 2004; Mesleh et al., 2007; Nielsen et al., 2000; Perrin et al., 1998 Fig. 7 ). The presented mechanism represents our current understanding of the mechanism of receptor modulation by nonpeptide ligands, a mechanism that potentially provides a straightforward, intuitive and quantitative framework to evaluate the receptor mechanism of other nonpeptide ligands. However, we cannot rule out the possibility that a different mechanism could also explain the experimental findings.
The findings of this study are also potentially relevant to other receptor systems.
The graded intrinsic activity of nonpeptide ligands, from inverse agonism to partial agonism, validates the hypothesis that the transmembrane domain of Class B GPCR's modulates signaling. This finding has also been demonstrated with small peptide fragments on the PTH1 receptor, with activity varying from inverse agonism to full agonism (Shimizu et al., 2005) . The partial agonism of NBI 77173 indicates that small, low molecular weight ligands can activate a Class B GPCR. This is strongly demonstrated by nonpeptide full agonists of the glucagon-like peptide-1 receptor (Knudsen et al., 2007) . The very low constitutive activity of the CRF 1 receptor might be common to the Class B GPCR family, for which there are few if any previous reports of constitutive activity via an unmodified receptor. With respect to allosteric modulators of GPCR's, conformational plasticity has also been invoked to explain the action of Class C GPCR allosteric modulators (Parmentier et al., 2002) . Allosteric modulators of the CB1 receptor, a Class A GPCR, have been demonstrated to enhance agonist binding but antagonize agonist signaling (Price et al., 2005) , potentially consistent with Mechanism 2
This article has not been copyedited and formatted. The final version may differ from this version. described in this study for the CRF 1 receptor. With respect to GPCR's generally, the CRF 1 receptor might represent a good candidate for crystallization studies to further elaborate GPCR structure beyond the X-ray crystal structures of the Class A GPCR's rhodopsin (Palczewski et al., 2000) and β 2 adrenergic receptor (Rasmussen et al., 2007) .
Obtaining diffraction-quality crystals is facilitated by conformational stability, a requirement that could be aided by the very low constitutive activity of the CRF 1 receptor and the ability to further stabilize the inactive conformation with a nonpeptide inverse agonist (Rasmussen et al., 2007) . The very high levels of CRF 1 receptor expression in mammalian expression systems (up to 100 pmol/mg) could also be useful in obtaining sufficient yields of functional, authentically-processed protein.
In summary, this study further elaborates the mechanism of CRF 1 receptor regulation by nonpeptide ligands, evolving the mechanism to account for receptor conformational states. Two distinct mechanisms of antagonism were identified, which are consistent with the stabilization of different conformational states, potentially allowing the design of nonpeptide ligands of more diverse chemical structure. These findings will be useful in the further development of nonpeptide ligands targeting the CRF 1 receptor as potential therapies for anxiety, depression and other stress-related disorders. forskolin. This value was measured as the 'no ligand' asymptote of the curve fit. R1 and R2 refer to the chemical structure in Fig. 1C . (Fig. 3 , Table 2 ), and allosteric modulation of CRF binding (G-protein-uncoupled receptor) is represented as the observed cooperativity factor C CRF (Fig. 2 , Table 1 ). The dashed line is a linear regression fit, and the solid line is the best fit by a four parameter-logistic equation. representative experiments performed three times. R1 and R2 refer to the chemical structure in Fig. 1C . Fig. 7 . Two-domain receptor state model of nonpeptide antagonism of the CRF 1 receptor. CRF binds to the CRF 1 receptor according to a two-domain model (Grace et al., 2007; Hoare et al., 2004; Mesleh et al., 2007; Nielsen et al., 2000; Perrin et al., 1998 This article has not been copyedited and formatted. The final version may differ from this version. This article has not been copyedited and formatted. The final version may differ from this version. This article has not been copyedited and formatted. The final version may differ from this version. 
Fig. 7
